Loading
Current blood tests for leftover cancer track a few dozen mutations and miss low-level disease. Whole-genome and error-corrected methods integrate signal across thousands of tumour-specific sites plus methylation and fragment features, reaching detection near one part per million in research settings; cost, turnaround and reproducibility are the barriers.
Whole-genome and error-corrected duplex approaches integrate signal across thousands to millions of tumour-specific sites, plus fragmentomic and methylation features, reaching detection limits reported near one part per million in research settings. Cost, turnaround and bioinformatics reproducibility are the barriers, not biology. If the limit of detection falls by two orders of magnitude, ctDNA-negative results become genuinely informative.
Shares Foresight Diagnostics, Variant allele frequency (VAF), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease.
Shares Variant allele frequency (VAF), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), The hardest cancers are found late.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Whole-exome & whole-genome sequencing.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).